Skip to content

Clinical efficacy evaluation and biomarker exploration of ICS/LABA in the treatment of chronic cough

Clinical efficacy evaluation and biomarker exploration of ICS/LABA in the treatment of chronic cough

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074815
Enrollment
Unknown
Registered
2023-08-17
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic cough

Interventions

Patients with chronic cough:none

Sponsors

Shandong Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-80 years old; (2) Chronic cough lasting for = 8 weeks or 3 weeks with a history of similar illness, and no significant abnormalities in chest CT; (3) Meet any of the following criteria: ? FeNO = 25ppb; ? The total IgE exceeds the normal range; ? Blood EOS = 0.1 * 10 ^ 9/L; (4) Before being included in the queue, it is necessary to sign an informed consent form and be able to participate in the research protocol and conduct follow-up according to the protocol.

Exclusion criteria

Exclusion criteria: (1) Within four weeks before enrollment, systemic corticosteroids, ICS or ICS combined with LABA or ICS combined with LABA+LAMA were used; Or acute respiratory infections may occur; (2) Suffering from clearly diagnosed chronic respiratory diseases, such as COPD, cystic fibrosis, bronchiectasis, interstitial lung disease, tuberculosis, lung cancer, etc; (3) Patients have known important risk factors for cough, including but not limited to: taking ACEI/ARB drugs; (4) Patients with serious systemic diseases, including heart failure, renal failure, liver failure, but basic diseases such as hypertension, coronary heart disease, diabetes do not need to be excluded (basic diseases are stable, only need drug maintenance), and maintain the use of the original drug regimen; (5) Women of childbearing age who are currently pregnant or breastfeeding; (6) Individuals who have received immunosuppressive therapy or participated in clinical research three months prior to enrollment.

Design outcomes

Primary

MeasureTime frame
Visual analogue scale,VAS;Reflux symptom index,RSI;Hull airway reflux questionnaire,HARQ;Asthma Control Questionnaire 5 ,ACQ-5;The Leicester Cough Questionnaire,LCQ;

Secondary

MeasureTime frame
Pulmonary function;

Countries

China

Contacts

Public ContactLiu Yi

Shandong Provincial Hospital Affiliated to Shandong First Medical University

yiliu-sdu@163.com+86 151 6888 8626

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026